BIOTA ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Continues Investigation of Biota Pharmaceuticals, Inc.; Investors Encouraged to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)--

Shareholder rights law firm Johnson & Weaver, LLP continues its investigation into whether certain officers and directors of Biota Pharmaceuticals, Inc, BOTA violated state or federal laws. Biota Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of anti-infective products.

On August 1, 2014 Biota announced its experimental influenza drug failed to meet the main goal in a mid-stage study. In April 2014 the U.S. Department of Health and Human Services pulled out of a contract to support the drug's development. The contract provided up to $231 million in financial support for the development of laninamivir octanoate for the treatment of influenza A and B in the United States.

If you have information that could assist in this investigation, including former employees and others, or if you are a Biota shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonandweaver.com) by email or by phone at 619-814-4471.

About Johnson & Weaver, LLP:

Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151009005694/en/